KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.

Kailun Fei, Jie Zhao, Jiachen Xu, Jianchun Duan, Chengcheng Li, Wenchuan Xie, Jia Zhong, Guoqiang Wang, Yu Xu, Boyang Sun, Rui Wan, Hua Bai, Qinxiang Guo, Wei Guo, Shangli Cai, Zhijie Wang, Jie Wang

Adv Sci (Weinh) 12(48) e06565

PMID41287887
PMCIDPMC12752622
DOI10.1002/advs.202506565
发表日期2025-11-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Predictive biomarkers are urgently needed for first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) in advanced non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) reflects tumor burden and immunogenicity, potentially identifyinging of patients suitable for ICI-chemo. In this study, pre- and on - treatment tissue and plasma samples are prospectively collected and analyzed from the randomized phase III CHOICE-01 trial comparing ICI - chemo versus chemotherapy alone in advanced NSCLC. Pre-treatment tissue and plasma samples, as well as on-treatment plasma samples, are prospectively collected. Tumor-informed ctDNA detection is based on tissue-identified mutations. Among patients with tumor-informed ctDNA positivity, those receiving ICI-chemo experienced significantly improved-free survival (PFS) and overall survival (OS) compared to those receiving chemotherapy alone (PFS: HR 0.45, 95% CI 0.34-0.60; OS: HR 0.66, 95% CI 0.49-0.88; p = 0.0045). In contrast, no significant differences in PFS or OS are observed between treatment arms in the ctDNA-negative subgroup. The predictive value of tumor-informed ctDNA is independent of other immune biomarkers and superior to other ctDNA metrics. Validation in a combined cohort from RATIONALE 304/307 trials shows similar results. Furthermore, ctDNA clearance during treatment correlates with better clinical outcomes (log-rank p = 0.0004 for OS and p = 0.044 for PFS).

KM 提取结果

3 个 Figure · 10 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2 Predictive role of tumor‐informed ctDNA in the CHOICE‐01 cohort. A,B). Kaplan‐Meier curves comparing progression‐free survival (PFS) between ICI‐chemo and chemotherapy in patients with ctDNA‐negative or ctDNA‐positive status. Upper, Kaplan‐Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of ICI‐chemo versus chemotherapy. C,D). Kaplan‐Meier curves comparing overall survival (OS), ICI‐chemo, and chemotherapy in patients with tumor‐informed ctDNA‐ or tumor‐informed ctDNA+. Upper, Kaplan‐Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of chemo‐ICI versus chemotherapy alone. The hazard ratios, corresponding 95% confidence intervals, and statistical significance of the difference were computed using the Cox proportional hazards model.

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
C

OS

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Figure 5

Figure 5 Dynamic change of tumor‐informed ctDNA status predicts PFS and OS as a complementary method to imaging. A. Schema of analysis. B‐C. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) between different ctDNA dynamic change groups among patients who were treated with ICI‐chemo in the tumor‐informed ctDNA positive group. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model. D‐E. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) in patients who were treated with ICI‐chemo stratified by radiographic response in on‐treatment ctDNA‐negative (baseline negative or turned negative at C3D1) and on‐treatment ctDNA‐positive (baseline positive or turned positive at C3D1) populations. P values were calculated by the log‐rank test.

B

Overall survival

Figure 5 · Panel B

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
C

Progression-free survival

Figure 5 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Overall survival

Figure 5 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 3:extreme upward reversal曲线 4:extreme upward reversal
查看结果
E

Progression-free survival

Figure 5 · Panel E

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel E 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 4 条,实际恢复 2 条曲线 1:extreme jump曲线 2:extreme jump曲线 3:short span
查看结果
KM Figure2 个面板

Figure 6

Figure 6 Predictive role of tumor‐informed ctDNA in the RATIONALE‐304/307 cohort. A‐B. Kaplan–Meier curves comparing progression‐free survival (PFS) among patients who were treated with ICI‐chemo versus chemotherapy in patients with tumor‐informed ctDNA+ or tumor‐informed ctDNA‐. Upper, Kaplan–Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of chemo‐ICI versus chemotherapy. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model. C. Forest plot depicting the comparison of ICI‐chemo and chemotherapy in tumor‐informed ctDNA+ and tumor‐informed ctDNA‐ groups, non‐lung squamous cell carcinoma (non‐LUSC) and lung squamous cell carcinoma (LUSC), respectively. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model.

A

progression-free survival

Figure 6 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

progression-free survival

Figure 6 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Study schema and the comparison of ITT and BEP. Schema of analysis. Specifically, a total of 465 patients were enrolled in the CHOICE‐01 study and randomized at a 2:1 ratio to the PD1 inhibitor combined with chemotherapy and the chemotherapy arm. Among them, 393 patients with tumor samples and plasma samples were defined as the biomarker evaluable population. Blood samples were collected at Day 1 at 1st cycling (C1D1) and at Day 1 at 3rd cycling (C3D1). The tissue samples were sequenced by whole‐exon sequencing, and blood samples were sequenced with a 520‐gene panel‐based deep sequencing.
非 KM Figure
Figure 3Figure 3 Genomic heterogeneity contributing to the tumor‐informed ctDNA status at baseline. A–H). Comparison the weighted genome instability index A), ploidy B), loss of heterozygosity C), tumor mutation burden (D), neoantigen (E), tumor antigenic peptide‐strong binder (F), tumor antigenic peptide‐weak binder (G), and high‐affinity tumor neoantigens (H) between the tumor‐informed ctDNA+ and ctDNA‐ groups. P values were calculated by the Mann‐Whitney U test. I. Oncoprint showing the alterations of driver mutation in the tumor‐informed ctDNA+ and tumor‐informed ctDNA‐ groups. P values were calculated by the Chi‐squared test. J). Comparison of altered mutation pathways between the tumor‐informed ctDNA+ and ctDNA‐ groups. P values were calculated by the Chi‐squared test.
非 KM Figure
Figure 4Figure 4 Predictive role of tumor‐informed ctDNA in the context of immune biomarkers. Comparison of PFS between ICI‐chemo and chemotherapy in tumor‐informed ctDNA+ and tumor‐informed ctDNA‐ groups, respectively, according to subgroups by immune biomarkers. P values were calculated using the log‐rank test. The HRs, HR interaction, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model.
非 KM Figure